Kayla A. Holder

494 total citations
17 papers, 352 citations indexed

About

Kayla A. Holder is a scholar working on Immunology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Kayla A. Holder has authored 17 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 6 papers in Infectious Diseases and 5 papers in Epidemiology. Recurrent topics in Kayla A. Holder's work include Immune Cell Function and Interaction (9 papers), T-cell and B-cell Immunology (7 papers) and SARS-CoV-2 and COVID-19 Research (6 papers). Kayla A. Holder is often cited by papers focused on Immune Cell Function and Interaction (9 papers), T-cell and B-cell Immunology (7 papers) and SARS-CoV-2 and COVID-19 Research (6 papers). Kayla A. Holder collaborates with scholars based in Canada, United Kingdom and United States. Kayla A. Holder's co-authors include Michael D. Grant, Rodney S. Russell, Suneale Banerji, Louise A. Johnson, David G. Jackson, Gennaro Prota, Uzi Gileadi, Vincenzo Cerundolo, Yaowaluck Maprang Roshorm and Tomáš Hanke and has published in prestigious journals such as Nature Immunology, The Journal of Immunology and PLoS ONE.

In The Last Decade

Kayla A. Holder

15 papers receiving 352 citations

Peers

Countries citing papers authored by Kayla A. Holder

Since Specialization

Citations

This map shows the geographic impact of Kayla A. Holder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kayla A. Holder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kayla A. Holder more than expected).

Fields of papers citing papers by Kayla A. Holder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kayla A. Holder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kayla A. Holder. The network helps show where Kayla A. Holder may publish in the future.

Co-authorship network of co-authors of Kayla A. Holder

This figure shows the co-authorship network connecting the top 25 collaborators of Kayla A. Holder. A scholar is included among the top collaborators of Kayla A. Holder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kayla A. Holder. Kayla A. Holder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection 2024 ·The Journal of Immunology ·Kayla A. Holder, (unknown), (unknown), (unknown), (unknown), (unknown), Rodney S. Russell, Michael D. Grant	0
2	Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2 2023 ·JCI Insight ·Michael D. Grant, Kirsten Bentley, Ceri A. Fielding, (unknown), (unknown), (unknown), Eddie C. Y. Wang, Richard J. Stanton, Kayla A. Holder	9
3	Cellular Immune Responses to SARS-CoV-2 in Exposed Seronegative Individuals 2023 ·Viruses ·(unknown), Kayla A. Holder, (unknown), (unknown), Rodney S. Russell, Michael D. Grant	4
4	Characteristics of Vaccine- and Infection-Induced Systemic IgA Anti-SARS-CoV-2 Spike Responses 2023 ·Vaccines ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kayla A. Holder, Rodney S. Russell, Michael D. Grant	3
5	Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection 2022 ·npj Vaccines ·Kayla A. Holder, (unknown), (unknown), Rodney S. Russell, Michael D. Grant	13
6	Few SARS-CoV-2 infections detected in Newfoundland and Labrador in the absence of Public Health Laboratory-based confirmation 2022 ·PLoS ONE ·(unknown), (unknown), (unknown), (unknown), Kayla A. Holder, Rodney S. Russell, Michael D. Grant	5
7	TIGIT blockade enhances NK cell activity against autologous HIV‐1‐infected CD4⁺ T cells 2021 ·Clinical & Translational Immunology ·Kayla A. Holder, (unknown), Michael D. Grant	19
8	TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir 2020 ·Frontiers in Cellular and Infection Microbiology ·Kayla A. Holder, Michael D. Grant	17
9	Cytomegalovirus-Driven Adaption of Natural Killer Cells in NKG2Cnull Human Immunodeficiency Virus-Infected Individuals 2019 ·Viruses ·(unknown), Kayla A. Holder, Neva J. Fudge, Michael D. Grant	9
10	Human cytomegalovirus IL-10 augments NK cell cytotoxicity 2019 ·Journal of Leukocyte Biology ·Kayla A. Holder, Michael D. Grant	15
11	Origins of natural killer cell memory: special creation or adaptive evolution 2018 ·Immunology ·Kayla A. Holder, (unknown), Michael D. Grant	11
12	Natural Killer Cells Adapt to Cytomegalovirus Along a Functionally Static Phenotypic Spectrum in Human Immunodeficiency Virus Infection 2018 ·Frontiers in Immunology ·Kayla A. Holder, Julie Lajoie, Michael D. Grant	10
13	Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1 2017 ·Nature Immunology ·Louise A. Johnson, Suneale Banerji, (unknown), Uzi Gileadi, Gennaro Prota, Kayla A. Holder, Yaowaluck Maprang Roshorm, Tomáš Hanke, Vincenzo Cerundolo, Nicholas W. Gale, David G. Jackson	146
14	Modulation of the strength and character of HIV-specific CD8+ T cell responses with heteroclitic peptides 2017 ·AIDS Research and Therapy ·Kayla A. Holder, Michael D. Grant	0
15	Rapid Lymphatic Dissemination of Encapsulated Group A Streptococci via Lymphatic Vessel Endothelial Receptor-1 Interaction 2015 ·PLoS Pathogens ·Nicola N. Lynskey, Suneale Banerji, Louise A. Johnson, Kayla A. Holder, Mark Reglinski, Peter A. C. Wing, (unknown), David G. Jackson, Shiranee Sriskandan	36
16	Natural Killer Cell Function and Dysfunction in Hepatitis C Virus Infection 2014 ·BioMed Research International ·Kayla A. Holder, Rodney S. Russell, Michael D. Grant	14
17	Hepatitis C Virus–Infected Cells Downregulate NKp30 and Inhibit Ex Vivo NK Cell Functions 2013 ·The Journal of Immunology ·Kayla A. Holder, (unknown), Maureen Gallant, Rodney S. Russell, Michael D. Grant	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact